# Argonaut Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/argonaut-therapeutics

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Latest round: Seed (Oct 19, 2016)
- Investors on record: 1

## About

Founded in 2016 and based in Oxford, UK, Argonaut Therapeutics Limited operates as a biotechnology company that conducts research and development of new cancer drugs. In January 2023, Celleron Therapeutics Limited, a portfolio company of WOORI Venture Partners, Korea Investment Partners, NHN Investment, and IMM Investment, merged with Argonaut Therapeutics Limited to form IngenOx Therapeutics Limited. Argonaut Therapeutics specializes in developing novel epigenetic therapies targeting abnormal arginine methylation. Argonaut’s lead programs focus on inhibitors of protein arginine methyltransferase 5 (PRMT5), aiming to restore natural cell death mechanisms in malignant cells. Leveraging its proprietary platforms, EXACT™ and ADEPT™, the company developed drug candidates such as AT101, which entered Phase I trials for solid tumors.

## Funding rounds

- Seed, Oct 19, 2016 — Oxford Sciences Enterprises

## Investors

- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed